Background-Given the controversy regarding whether carotid endarterectomy (CEA) or carotid artery stenting (CAS) may be superior for stroke prevention, it is uncertain how recent clinical evidence, guidelines, and reimbursement policies have influenced the volume and outcomes after these procedures.
S troke is the third leading cause of death in the United States, imposing enormous economic burden on individuals and our society. 1, 2 Extracranial internal carotid artery disease is an important cause of ischemic stroke, and treatment of carotid artery disease has been a focus of intense clinical investigations during the past several decades. 3 Several randomized trials established the benefit of carotid endarterectomy (CEA) over medical therapy in both symptomatic and asymptomatic patients. [4] [5] [6] However, many individuals are considered poor candidates for CEA because of advanced age, high-risk anatomic features (eg, prior radiation therapy or prior neck dissection/CEA), or medical comorbidities, and have higher rates of postoperative adverse events.
Carotid artery stenting (CAS) was introduced as a minimally invasive endovascular alternative to CEA, and numerous trials have compared the efficacy and safety of CAS with that of CEA. [7] [8] [9] [10] [11] Several European trials demonstrated an increased rate of adverse events after CAS; however, there were major criticisms with design and conduct of these trials, including lack of mandatory use of embolic protection devices and inexperience of CAS operators. [9] [10] [11] In contrast, the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) trial evaluated CAS as an alternative strategy for patients at high risk of adverse outcomes with surgical CEA, demonstrating CAS to be noninferior to CEA. 7 As a result of this trial and others, the US Food and Drug Administration approved CAS in 2004 for the treatment of both symptomatic and asymptomatic carotid artery stenosis in patients at high surgical risk.
The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) found that CAS has similar efficacy to CEA with respect to a composite end point of death, stroke, or myocardial infarction (MI) for standard surgical risk patients. 8 However, despite the equipoise of outcomes in standard risk patients, currently reimbursement by the Centers for Medicare and Medicaid Services for CAS is limited to high-surgicalrisk patients having ≥70% symptomatic stenosis and those who have symptomatic stenosis ≥50% or asymptomatic stenosis ≥80% and are enrolled in Food and Drug Administrationapproved clinical trials and postmarket registries. Using the Nationwide Inpatient Sample (NIS) database, we examined temporal trends in CAS and CEA use and in-hospital outcomes from 2001 to 2010 and compared in-hospital outcomes between CAS and CEA in patients with symptomatic and asymptomatic carotid artery disease.
Methods

Study Data
Data were obtained from the Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project-NIS files between 2001 and 2010. 12, 13 The NIS is a 20% stratified sample of all nonfederal US hospitals. The NIS contains deidentified information for 39 008 298 weighted discharges from 1051 hospitals and 45 states in 2010. Discharges are weighted based on the sampling scheme to permit inferences for a nationally representative population. 12 Each record in the NIS includes all procedure and diagnosis International Classification of Diseases (ICD) codes recorded for each patient's hospital discharge.
Identification of Sample
From January 2001 through December 2010, hospitalizations identifying CEA were selected using the ICD, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code 38.12 in any of the 15 procedure fields. Procedure code 00.63 was used to identify CAS. Because the procedure code 00.63 came into use after October 2004, CAS was identified by using the modified algorithm of Goodney et al 14 for the years 2001 through September 2004. Two percent of CAS cases and 0.2% of CEA cases underwent both procedures during the single hospitalization and were excluded from this analysis.
Definitions and End Points
Patient-level and hospital-level variables were included as baseline characteristics. The Agency for Healthcare Research and Quality (AHRQ) comorbidity measures based on the methods by Elixhauser et al 15 were used to identify comorbid conditions. To distinguish between asymptomatic and symptomatic carotid artery disease, discharge records with a diagnosis of amaurosis fugax, transient visual loss, transient paralysis of limb, carotid artery stenosis and occlusion with cerebral infarct, transient cerebral ischemia, or cerebral artery occlusion were classified as symptomatic carotid artery disease. The main outcome measures were in-hospital all-cause mortality, postprocedural stroke, acute MI, and major adverse events (MAEs). In-hospital MIs were identified by the ICD-9 codes 410.0 to 410.9. Postprocedural stroke was identified by ICD-9 code 997.02. MAE was defined as death after procedure, stroke, or MI.
Statistical Analyses
We calculated procedure rates as the weighted number of CAS and CEA procedures, divided by 20% of the total number of US adults during the same periods. Estimates of the US adult population between 2001 and 2010 were obtained from the US Census Bureau. 16 Trends in the annual rates of CAS and CEA were assessed using the autoregressive integrated moving average model for time series. Rates of CAS and CEA use over time were compared in patients subgrouped according to age (<80 versus ≥80 years), sex, race, and symptom status (asymptomatic versus symptomatic). To compare baseline characteristics, in-hospital care patterns, and outcomes with respect to receiving CAS or CEA, Mann-Whitney Wilcoxon nonparametric tests were used for continuous variables and Pearson χ 2 tests were used for categorical variables.
Unadjusted in-hospital outcome rates were calculated in the overall population and the subgroups of patients with symptomatic versus asymptomatic carotid artery disease. Multivariable logistic regression analyses were used to compare outcomes between CAS and CEA adjusting for other potential predictors that had significant univariate association with outcomes (P<0.05). For all regression analyses, the Taylor linearization method with replacement design was used to compute variances. To further adjust for potential selection bias for CAS versus CEA, a logistic propensity score was calculated using a multilevel model including all covariates used in the primary analysis. The multilevel model propensity score was then incorporated as an additional variable in the weighted logistic regression models. 17 Furthermore, propensity score-matched logistic regression modeling was performed. After PROC GLIMMIX estimation of propensity score, we used PROC LOGISTIC to analyze the data set created by PROC GLIMMIX (c statistic=0.861). Using previously described methodology, each CAS case was matched with 3 CEA controls for statistical efficiency by predicted propensity scores. 18, 19 Furthermore, we evaluated the success of the propensity score-matched model by examining the standardized differences in baseline characteristics before and after propensity score matching ( Table I in the Data Supplement).
The effects of clinical indication (symptomatic versus asymptomatic) on the relationship between CAS and the outcomes were assessed by including interaction terms between procedure performed (CAS or CEA) and the symptom status in the propensity
WHAT IS KNOWN
• Many individuals are considered poor candidates for carotid endarterectomy because of advanced age, high-risk features (eg, prior radiation therapy or prior neck dissection/carotid endarterectomy) or medical comorbidities and have higher rates of postoperative adverse events.
• The Carotid Revascularization Endarterectomy
Versus Stenting Trial (CREST) found that carotid artery stenting has similar efficacy to carotid endarterectomy with respect to a composite end point of death, stroke, or myocardial infarction for standard surgical risk patients.
WHAT THE STUDY ADDS
• In our analysis of real-world experience in the United States, carotid artery stenting is generally performed in a higher risk cohort, with more cardiovascular comorbidities.
• Carotid artery stenting was associated with worse in-hospital outcomes, partly attributable to selection and ascertainment bias.
• There has been a substantial improvement in overall and individual outcomes of death, myocardial infarction, death/stroke, and major adverse events after carotid artery stenting since 2001. score-adjusted models. Lastly, logistic regression was performed to examine trends in outcomes during the 10-year period. To evaluate changes in adverse outcomes over time in both CAS and CEA population, the propensity score-adjusted regression modeling was used to calculate adverse events for individual years, with year 2001 serving as a reference year. All statistical tests were 2 sided, and a P value of <0.05 was set a priori to be statistically significant. All the regression analyses were conducted using SAS, version 9.2 (SAS Institute, Cary, NC) and SAS-Callable SUDAAN, version 10.0.1 (Research Triangle Institute, NC).
Results
Study Population
For each year from 2001 to 2010, the NIS data set included discharges from 517 hospitals in 2001 to 471 hospitals in 2010 that performed CEA and 163 hospitals in 2001 to 229 hospitals in 2010 that performed CAS. Of 388 358 479 discharge records reviewed from 2001 to 2010, 124 265 patients underwent CAS (9%) and 1 260 647 underwent CEA (91%). Table 1 compares baseline characteristics for the CAS and CEA groups. CAS population was slightly younger, more likely to be male, have previous percutaneous intervention, angina, chronic ischemic heart disease, chronic renal failure, heart failure, or peripheral vascular disease, were less likely to be white, and have asymptomatic carotid disease or hypertension. CAS was more frequently used in large, teaching hospitals and in the northeast than CEA.
Trends in Incidence of CAS and CEA, 2001 to 2010
The annual rate of all carotid revascularization procedures ( Projected to the entire US population, these trends suggest that 52 416 fewer CEA surgeries and 9621 more CAS procedures were performed in 2010 as compared with 2001. Given the 9% decrease in the number of hospitals performing CEA, the decline in the rates of CEA reflects a 34% reduction in the median caseload of 109 per hospital in 2001 to 72 cases in 2010. Although there was an increase in the rate of CAS over time, median caseload only increased from 10 to 24 from 2001 to 2010 attributable to concomitant increase in the number of hospitals performing CAS. Figure 2 demonstrates the frequency of CEA and CAS use over time in key subgroups of age, sex, race, and symptom status. A steady decrease in frequency of CEA from 2001 to 2010 was observed in all subgroups (P<0.05 for all subgroups), with the most significant decline in the high-risk subgroup of elderly, aged ≥80 years (P<0.001).
Outcomes of CAS and CEA
The incidence of in-hospital death (1.2% versus 0.6%; P<0.001), postprocedural MI (1.3% versus 1.0%; P=0.001), postprocedural stroke (1.9% versus 1.0%; P<0.001), and MAEs (4.4% versus 2.6%; P<0.001) were greater in CAS versus CEA groups, and CAS was associated with significantly greater odds of all outcomes in univariate logistic regression analyses ( Table 2 ). After adjustment for other potential predictors of outcome using multivariate logistic regression analyses, CAS remained an independent predictor of death, stroke, and MAEs, but not MI. CAS remained significantly associated with increased death, stroke, and MAEs after multivariate adjustment including a propensity score (model No. 2) and in a subgroup of the population matched by propensity score (model No. 3; Table 2 ). These results were consistent when adjusted odds of outcomes for CAS versus CEA were performed for each individual year ( Table II in the Data Supplement).
Outcomes in Symptomatic and Asymptomatic Patients
In the asymptomatic cohort, the unadjusted rates of MIs (1.0% versus 1.0%; P=0.90) were not significantly different between CAS versus CEA, whereas the rates of death (0.6% versus 0.5%; P=0.005), stroke (0.8% versus 0.5%; P<0.001), and MAEs (2.1% versus 1.8%; P<0.001) were higher in CAS versus CEA. In the symptomatic cohort, the unadjusted rates of deaths, MI, stroke, and MAEs were all significantly higher in the CAS versus CEA group (5.1% versus 1.9% for death, 3.1% versus 1.6% for MI, 8.6% versus 6.1% for stroke, 15.2% versus 8.4% for MAEs; P<0.001 for all outcomes). In asymptomatic patients (Table 3) , after multivariable adjustment, CAS seemed to be associated with decreased adjusted odds of MI and increased odds of stroke. Importantly, in aggregate, CAS was no longer predictive of MAEs in asymptomatic patients after multivariable adjustment. In symptomatic patients after propensity score-adjusted multivariable logistic regression analysis, CAS was associated with significantly higher odds of death, death/stroke, and MAEs. CAS in symptomatic patients was associated with lower odds of stroke than when CAS was performed in asymptomatic patients (P<0.001 for interaction).
Trends for Outcomes of CAS and CEA, 2001 to 2010
Adjusted odds of adverse outcomes over time were compared for individual years with those in 2001 in 
Discussion
There are several, important findings in this nationally representative sample of US hospital discharge records comparing the use of CAS and CEA between 2001 and 2010. First, rates of overall carotid revascularization procedures have decreased by 34% from 2001 to 2010. This decrease was primarily driven by a reduction in the number of CEA, despite a small and steady increase in CAS nationally. Second, carotid revascularization is largely performed in asymptomatic (>80%) patients. Third, as expected because of reimbursement restrictions imposed by Centers for Medicare and Medicaid Services, CAS is generally performed in a higher risk cohort, with more cardiovascular comorbidities. Fourth, CAS was associated with worse postprocedural outcomes, although after multivariate adjustment the negative impact of CAS was partly attenuated. Fifth, in the asymptomatic cohort of patients, the largest group examined in this analysis, a 37% relative increase in the adjusted risk of postprocedural stroke with CAS versus CEA is balanced with a 21% relative reimbursement criteria imposed by the Centers for Medicare and Medicaid Services. The decline in the incidence of CEA cannot be explained simply by introduction of an alternative, less invasive CAS strategy, as the incidence of CEA continued to steadily decline after 2006, when use of CAS was no longer increasing. More likely, this decline is attributable to concerns in the medical community about the value of carotid revascularization (CEA or CAS) for primary prevention of stroke, potentially important improvements in medical management of carotid disease since 1990s, as well as concerns about risks/ benefits of revascularization in high-risk, asymptomatic elderly patients, in whom the prevalence of carotid disease is high. Despite similar overall efficacy and safety of CAS in comparison with CEA in landmark trials, only 13.5% of patients who underwent carotid revascularization underwent CAS. 7, 8 Given a recent survey demonstrating that a significant portion of patients still prefer CAS over CEA despite being quoted with a slightly higher periprocedural risks in comparison with CEA, one has to wonder whether patient preference is incorporated into the decision making in terms of carotid revascularization. 21 Recent studies have demonstrated a clear relationship between operator volume and improving outcomes after CAS. [22] [23] [24] Although there was an increase in the rate of CAS over time in our study, median hospital caseload only increased from 10 to 24 from 2001 to 2010 because of concomitant increase in the number of hospitals and likely operators performing CAS. This suggests that current rates of CAS may lead to inadequate volume for a significant portion of the operators to maintain procedural competency.
As previously noted, the majority of carotid artery procedures were performed in asymptomatic patients in this analysis. Because of inherent limitations of administrative databases, including NIS registry, it is plausible that the proportion of symptomatic carotid artery patients was underestimated. 25 However, this report is consistent with recent studies demonstrating that CAS and CEA are still predominantly performed in asymptomatic patients for primary prevention of stroke. 26, 27 Despite small increase in the median case volume per year for hospitals performing CAS >10 years, the individual hospital volumes remain relatively low. It is reassuring that despite relatively low volumes of CAS procedures being performed and the rise in the number of CAS hospitals/operators over time, the outcomes after CAS continue to improve, even in selected high-surgical-risk patients. Given the findings of previous studies demonstrating a clear higher case volume-improved outcomes relationship after CAS, it is conceivable that even more improvement might have occurred in CAS outcomes if the volume of CAS procedures had continued to increase. 24, 28, 29 The mortality rate associated with CAS (1.2%) in our study was similar to previous studies of high-surgical-risk patients, such as the SAPPHIRE trial (1.2%), whereas periprocedural stroke rate for the CAS group (1.9%) was lower than some of previously reported rates (3.6% for SAPPHIRE and 4.1% for CREST). 7, 8 It is possible that there could be under-reporting of complications in databases of hospital discharges. However, we would expect such under-reporting to occur equally in the CAS and CEA cohorts and, therefore, would still result in effective comparison of the 2 modalities. In this analysis, CAS was associated with an increased risk of death, stroke, death/stroke, and MAEs despite propensity score-adjusted or -matched analyses. These results are in contrast to the findings of the randomized SAPPHIRE and CREST trials, 7, 8 where the MAE rates were noninferior between CAS and CEA procedures. These results may be reflective of the real-world experience and selection bias, wherein high-surgical-risk patients are preferentially treated with CAS. Furthermore, cardiac biomarkers are frequently routinely monitored in most carotid registries in addition to protocol mandated, comprehensive neurological examination after CAS. Therefore, the ascertainment bias may further contribute to an increase in adverse outcomes seen in CAS-treated patients. Because some of the high-risk criteria used in randomized trials to risk stratify patients for CEA, such as anatomic and clinical characteristics, were not available in the NIS database, it is possible that CAS cohort retained other high-risk features despite comprehensive propensity score-matched adjustment. Symptomatic patients undergoing carotid artery revascularization experienced more adverse postprocedural events, consistent with prior reports. 30 In fact, the incidence of death or stroke was 12.8% for CAS and 7.3% for CEA, both well >6%, considered to be an acceptable rate of death/stroke by the American Heart Association guidelines for performance of CEA or CAS in symptomatic patients, 31 raising concerns regarding proper selection of symptomatic patients undergoing carotid artery revascularization in the real-world setting. Despite the lack of clear clinical directive on which intervention may be superior on an individual basis, careful selection of patients with favorable anatomic features for CAS is essential to ensure low rates of periprocedural complications. 32 It is important to note that in comparison with our data, previous reports from the CAS postmarket surveys and CEA surveys have demonstrated significantly lower rates of death or stroke, particularly in symptomatic patients. 25, 33 Such findings can be partly explained by the fact that CAS is frequently performed in addition to intracerebral catheter-based treatment of acute stroke (eg, mechanical thrombectomy/thrombolysis). Because these high-risk patients could not be excluded from our analysis, the adverse event rates may appear disproportionately higher compared with studies in which such patients were excluded. In contrast to symptomatic patients, the incidence of death or stroke was low in the asymptomatic cohort for both CAS and CEA (1.2% for CAS and 0.9% for CEA), below the 3% acceptable by the American Heart Association guideline, suggestive that both procedures are relatively safe in the current US experience. This may be partly explained by the fact that asymptomatic cohort may not consist of only high-surgical-risk patients. A significant (and disproportionate to CEA) number of asymptomatic CAS patients is being referred for carotid restenosis after prior CEA and radiationinduced carotid stenosis. Both of these conditions are thought to represent lower stroke risks with treatment than de novo atherosclerotic lesions.
Recent data suggest a strong correlation between institutional and individual operator volume and outcomes after P values for trend were P=0.03 for death, P=0.09 for stroke, P=0.5 for myocardial infarction, P=0.03 for death/stroke, and P=0.05 for MAEs in the CAS group. P values for trend were P<0.001 for death, P=0.6 for stroke, P=0.003 for myocardial infarction, P<0.001 for death/stroke, and P<0.001 for MAEs in the CEA group. CAS indicates carotid artery stenting; CEA, indicated carotid endarterectomy; CI, confidence interval; MAEs, major adverse events; OR, odds ratio; and PS, propensity score.
*Propensity score-adjusted multivariable logistic regression analysis.
CAS. 24, 28, 29 Importantly, our findings suggest that the risk of adverse outcomes after CAS and CEA has declined during the course of 10 years. Given that CEA has been performed for decades with minor modifications in recent years, the likely explanation for improving outcomes after CEA in the past 10 years may be attributable to a relative shift from CEA to CAS in high-risk patients. With relatively low yearly institutional and individual volumes of CAS, it seems that CAS learning curve phase could take several years, but over time it is likely responsible for improved procedural outcomes, similar to outcomes demonstrated in the landmark clinical trials. 7, 8 This finding is consistent with a recent study that demonstrated a decline in periprocedural death and stroke rates in CAS after regulatory approval and Medicare coverage leading to increased operator experience and continued regulatory oversight. 34 Given that CAS is relatively novel technology in comparison with CEA, CAS has already undergone evolution in patient selection, technological advances, and procedural skills with a steep learning curve. Therefore, CAS is associated with significant improvement in outcomes over time as has been demonstrated in the CREST trial as well as the current study. 8 Several limitations of this study should be acknowledged. First, this is a retrospective study based on data from NIS, with the sample designed to approximate the national distribution of key hospital characteristics. Our estimates for CAS and CEA were derived from 20% sample of US hospitals, and it is possible that CAS or CEA were either under-represented or over-represented by the sample. However, NIS has been used extensively to examine national healthcare trends, and its sampling design has been validated in numerous publications. Second, unmeasured confounders could not be accounted for despite our best efforts to comprehensively adjust for multiple available clinical variables. The NIS does not include detailed information about patient clinical characteristics, such as frailty, coronary anatomy, angina class, heart failure class, left ventricular function, medications, or smoking status. Given that currently only patients with high surgical risk are covered by the Centers for Medicare and Medicaid Services, it could be presumed, but not proven, that the above-mentioned factors are more commonly present in the CAS cohort. However, the absence of these variables complicates comparisons of carotid revascularization outcomes, and therefore a more detailed exploration of the drivers of the outcomes we observed is beyond the scope of this analysis. Third, we chose to study the time period from 2001 to 2010 to characterize trends in outcomes of CAS and CEA during 10 years. Given the rapid maturation of CAS following the Food and Drug Administration approval of CAS in 2004, inclusion of years 2001 to 2004 may have diminished a fair comparison of contemporary CAS versus CEA. Furthermore, previous analysis of the National Cardiovascular Data Registry-Carotid Artery Revascularization and Endarterectomy (NCDR-CARE) has demonstrated markedly different clinical characteristics in patients referred for CAS versus those referred for CEA. 35 Given persistent imbalance of patient characteristics undergoing CAS versus CEA despite the comprehensive nature of the NCDR-CARE, it is unlikely that the use of NIS database could eliminate all the differences between these 2 cohorts, even with propensity score matching analysis. In addition, NIS database provides only in-hospital outcomes. Therefore, our findings may not necessarily reflect 30-day and long-term outcomes after CAS and CEA, commonly examined in randomized trials. However, given that most adverse outcomes after carotid revascularization occur soon after the procedure, this analysis provides important insights regarding comparative effectiveness of CAS and CEA. Lastly, CAS is frequently performed in patients with acute stroke during catheter-based treatment. Although the number of patients undergoing catheter-based treatments is small relative to the overall number of CAS, inclusion of these high-risk patients may overestimate the rate of adverse outcomes after CAS in the symptomatic cohort.
Conclusions
In conclusion, the rate of carotid artery revascularization decreased steadily from 2001 to 2010, mainly driven by decline in use of CEA. In contrast, there was an increase in CAS procedures performed in the United States, reaching a plateau after 2006. CAS was associated with worse in-hospital outcomes compared with CEA, likely attributable to selection and ascertainment bias. Asymptomatic patients undergoing CAS versus CEA had similar adjusted rates of major adverse events. Outcome after CAS improved from 2001 to 2010, an observation that may have resulted from improvements in patient selection, operator skills, and technological advancements over time.
